The purpose is to determine whether the medication changes the number of sperm produced, measured as sperm concentration, compared with the placebo. Participants receive an injection once a week for several months and attend a few clinic visits where blood samples, body measurements and semen samples are collected to evaluate sperm count, hormone levels and other health markers. No surgery is involved, and the follow‑up period lasts about six months.

After surgery, participants receive the study medication through an IV while they stay in the recovery area known as the post‑anesthesia care unit. Their blood‑oxygen level (SpO2) is continuously checked, and pain intensity is recorded using a Numeric Rating Scale that runs from 0 (no pain) to 10 (worst pain). The observation period covers the first 24 hours after surgery, during which the number of doses given, any episodes of low oxygen, the need for supplemental oxygen, breathing rate, nausea, vomiting, and overall comfort are monitored.

The trial lasts several weeks, starting with a short period where the dose of the injection is gradually increased, followed by a maintenance phase where the dose stays the same. During the last two weeks of each treatment period, participants will wear a small sensor that continuously records glucose levels, known as a CGM, and will also have routine blood tests such as the average sugar level test called HbA1c. The study compares the results from the weeks when the active injection is used with the weeks when the placebo is used to determine any differences in blood sugar control and related measurements.

The purpose of the trial is to find out whether the medication is safe and works to protect bone health in this setting. After the first infusion, patients are followed for up to two years with regular check‑ups that include a low‑radiation test called a DXA scan to measure bone density, and they are monitored for any new fracture. The study records whether participants experience bone breaks and how their bone strength changes over time, while also keeping track of any side effects from the treatment.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

Participants will receive one of several commonly used antibiotics: amoxicillin combined with clavulanic acid taken by mouth, cloxacillin given through a vein, cefuroxime also given intravenously, and dicloxacillin taken orally. These medicines are standard treatments that doctors use to stop bacteria from growing after surgery.

During the study, small samples of blood (the liquid part of blood called plasma) and fluid from the surgical area will be collected at several time points after the antibiotic is given. The fluid is obtained with a tiny tube that gently draws out fluid from the tissue, a technique called microdialysis, which allows researchers to measure the amount of drug present over time. The collected samples are then analyzed to see how long the drug levels stay above the amount needed to stop bacterial growth.

The goal of the research is to find out whether a lower dose of the drug works just as well as the standard full dose for these patients. Participants are randomly assigned to receive either the reduced dose or the full dose, and they are monitored closely for about a week to see how they respond, including any need for life‑support measures or repeat clot events.

During the study, doctors watch for signs of improvement such as stable blood pressure, better oxygen levels, and the ability to breathe without extra machines. They also keep track of any serious bleeding problems. The overall plan is to compare the two dosing strategies to see if the lower amount can provide the same benefit with potentially fewer side effects.

The purpose of the study is to find out whether the spray can improve the sharpness of vision, known as visual acuity, compared with the placebo. Over several months, participants will use the spray daily and attend regular visits where standard eye tests are performed, such as reading letters on a chart, checking the area that can be seen without moving the eyes (visual field), and an eye scan called optical coherence tomography that measures the thickness of retinal layers. The study follows each person from the start of treatment through the end of the observation period to see how vision changes over time.

The purpose of the study is to determine whether the added intravenous dose speeds relief of symptoms compared with standard treatment alone. Participants are randomly assigned to receive either the study drug or the placebo, both in addition to the regular oral medication, and are followed for several weeks to record pain levels, use of pain‑relieving medicines, and any complications. After the initial treatment period, patients continue routine care and are observed for any further episodes or the need for surgery over the next months.

The purpose of the study is to determine whether long‑term treatment with acoramidis can improve the way the heart works and is safe to use. Heart function and structure are evaluated using imaging techniques such as Cardiac Magnetic Resonance and echocardiography, which create detailed pictures of the heart and help assess the amount of amyloid protein present.

During the trial, participants take the study medication each day for several years and attend regular clinic visits where heart scans and simple blood tests are performed. One key measurement is the LVEF, a number that shows how much blood the heart pumps out with each beat; improvements or stability in this value are used to gauge benefit. Any side effects or health changes are closely monitored throughout the study period.

The purpose of the study is to determine whether the combined vaccine prevents doctor visits or hospital stays caused by flu or COVID‑19 as well as, or better than, the two separate shots. Participants aged 65 years or older will receive either the combined vaccine or the two separate vaccines on the same day and will be observed for several months. Any illness that leads to a medical appointment, emergency care, or hospitalization will be recorded to assess the vaccine’s effectiveness.

Participants are randomly assigned to receive either the study drug or placebo on a regular schedule for several months. Throughout the trial, blood tests are performed to measure thyroid hormones (such as T3, T4, and TSH) and antibodies that affect the thyroid (TRAb). Researchers also monitor overall health, side effects, and quality of life using questionnaires. The study follows participants for up to 24 weeks to see how many can maintain normal thyroid function without antithyroid drugs and to assess any safety concerns associated with the treatment.

The purpose of the study is to find out whether it is possible to run a larger trial that tests whether this medication can safely reduce the long‑lasting pain that some patients experience after lung cancer surgery.

Participants who meet the basic criteria will be asked to join, receive the injection, and then complete a series of brief questionnaires about their pain and any side effects at several follow‑up visits. The study will track how many people agree to join, how many complete the treatment and follow‑up, and will collect information on how well the injection method is tolerated.

The purpose of the study is to determine whether the experimental drug, alone or together with the blood‑vessel‑blocking drug, can improve overall survival compared with the standard pill combination plus the blood‑vessel‑blocking drug.

Participants are randomly placed into one of three groups: one group receives the experimental drug alone, a second group receives the experimental drug combined with the blood‑vessel‑blocking drug, and a third group receives the standard pill combination together with the blood‑vessel‑blocking drug. Treatments are given in repeated cycles, and participants have regular clinic visits for check‑ups, blood tests, imaging scans, and monitoring for side effects. The study continues until the disease progresses or the treatment can no longer be tolerated.

The purpose of the study is to compare how well the new oral tablet, alone or combined with standard chemotherapy, works against standard chemotherapy alone in controlling the cancer. Participants are randomly assigned to one of the three groups and receive treatment in repeating 28‑day cycles. During the study, regular doctor visits, imaging scans, blood tests, and quality‑of‑life questionnaires are performed to track disease status and any side effects. Treatment continues until the cancer grows, side effects become unacceptable, or the study ends after about two years.

Randomly assigned means the chance decides which group a participant joins, helping to keep the comparison fair. Open‑label indicates that both the medical team and participants know which treatment is being given. A cycle refers to a set period of treatment followed by a short rest, typically one month. Progression means the cancer is getting larger or spreading, which doctors watch for using standard imaging methods.

The purpose of the trial is to determine whether this combination can achieve durable immunological control of the virus when antiretroviral therapy is stopped. After receiving the study infusions, participants will pause their regular ART under close medical supervision and will have regular blood tests to monitor viral levels and immune‑cell counts; if the virus rises above predefined thresholds or immune cells fall, treatment will be restarted.

During the entire study period, participants will be monitored for any side effects or laboratory changes, and any serious problems will be reported to the study team, with follow‑up extending for several months after the therapy interruption.

The purpose of the study is to see whether adding Rinatabart Sesutecan can keep the cancer from growing for a longer time compared with the usual treatment alone. Participants are randomly placed into one of the two groups after completing their second‑line chemotherapy, then they receive the assigned maintenance therapy for several months while doctors monitor their health through regular clinic visits and scans.

Progression‑free survival means the period during which the cancer does not get worse. Doctors use a set of rules called RECIST to measure whether tumors have grown or shrunk on imaging tests. To understand how the treatments affect overall well‑being, participants also complete a questionnaire known as the EORTC QLQ‑C30, which asks about symptoms, daily activities, and overall quality of life.

The purpose of the study is to see how many participants can stay on the intended dose after six months compared with usual care. Participants who have experienced statin intolerance – meaning they have had trouble tolerating cholesterol‑lowering drugs due to side effects – will take part in a N-of-1 trial, where each person tries the real medicine and the placebo at different times, acting as their own control.

During the trial, each person will follow a schedule of taking either the medication or the placebo for several weeks over a total of about 36 weeks, then continue to be followed for six months to record whether they are still taking the 20 mg dose. Throughout the study, participants will regularly note any side effects they experience and whether they continue the treatment.

The purpose of the study is to determine whether stopping the birth control pill influences how well depression improves and how well short‑term memory works while taking antidepressants. Participants are randomly assigned to either continue the pill or switch to a non‑active pill (placebo) for about eight weeks. All participants keep taking their antidepressant medication throughout the period.

During the eight‑week period, participants complete simple questionnaires that rate mood severity and perform brief word‑recall tests that measure the ability to remember spoken words. These checks are done at the start and at the end of the study to compare any changes between the two groups.

Participants will receive a weekly infusion for three years. Some will get the regular dose, others will receive one of two alternative doses, and a small group will receive a placebo. Lung health will be checked regularly with scans using computed tomography and simple breathing tests, and any side effects will be recorded. The study concludes after the three‑year treatment period.

The purpose of the research is to see whether the drug can be given safely and is well tolerated by people who have just been diagnosed with the disease. Participants will receive a subcutaneous injection of the medication using a pre‑filled syringe at regular intervals over a period of about one year, with clinic visits scheduled to monitor health and collect information.

During the study, doctors will track changes in a score called the BPDAI, which measures the number and size of blisters and the amount of skin affected. They will also ask participants to rate their itch on a simple 0‑10 scale, evaluate the impact on daily life and mood, and record any use of other skin‑care treatments. These assessments help determine how the drug affects the skin condition and overall well‑being.

All participants receive the standard drugs in R-mini-CHOP, which include the antibody rituximab and several chemotherapy agents. In the experimental group, patients also receive epcoritamab, which is given as a small injection under the skin (subcutaneous). The standard group receives only the usual chemotherapy and the antibody given either by vein (intravenous) or under the skin, depending on the usual practice.

Participants are randomly assigned to one of the two treatment plans and go through a series of treatment cycles over several months. After the treatment period, regular check‑ups are performed to see whether the cancer has disappeared completely (called complete remission) or whether it has returned. The study follows patients for a period of time after treatment to monitor their health and any side effects.

The purpose of the study is to evaluate whether the new scan can improve the detection and assessment of tumor lesions at the time of first diagnosis, during treatment, and if the disease returns. Participants will receive the injection, then lie on a scanning table while the machine takes images; this will be done at several visits that match the usual points when doctors check the disease. The images are read by doctors to see how well the new substance works compared with the standard one, and the overall experience of the children and their families is also recorded.

The purpose of the study is to find out which medicine better prevents low blood pressure (hypotension) while the patient is being treated before hospital admission. Participants who need pre‑hospital sedation and ventilation are randomly given either the test drug or the comparator drug. Their blood pressure and oxygen levels are monitored from the first reading in the ambulance until they leave the trauma centre, and their recovery is checked again about six months later.

During the observation period the study records any episodes of very low or very high blood pressure, as well as low oxygen levels, and later evaluates how well patients can perform everyday activities using standard rating scales that measure functional ability. No additional procedures beyond the emergency care needed for the injury are performed as part of the study.

The purpose of the study is to find out whether PIPE-791 can preserve breathing ability better than the placebo. Participants will take the study medication or placebo every day for about six months, with regular visits to check health, report any side effects, and undergo simple breathing tests. One of the key breathing tests measures forced vital capacity (FVC), which is the amount of air a person can push out of the lungs after taking a deep breath; this helps doctors see how the lungs are working. At selected visits, a special detailed X‑ray scan called HRCT will be used to look at the amount of scarring in the lungs. The study follows participants for the full treatment period to monitor safety and how well the drug works.

The purpose of the study is to assess the antitumor activity and safety of Rinatabart Sesutecan in participants with these advanced cancers. Participants will receive the study drug at regular intervals while being monitored through clinic visits, blood tests, and imaging scans to check for changes in tumor size and to record any side effects, known as adverse events. The study follows a schedule that spans several months, allowing researchers to observe how the cancer responds over time and to gather information on the medication’s tolerability.

The purpose of the study is to determine whether the first antibiotic combination works as well as, or better than, the second combination while being safe for patients. After enrollment, participants are randomly assigned to receive one of the two treatment regimens, which are started soon after hospital admission and continued for several days as decided by the treating doctors. Patients remain in the hospital for monitoring and are followed for about a month after the start of treatment.

Researchers will record whether a patient dies from any cause within 30 days and will check for signs of sudden loss of kidney function, known as acute kidney injury, during the same period. Kidney injury is identified when the kidneys stop filtering waste as well as they should, which can be detected through routine blood tests.

The purpose is to compare how well the cancer is controlled when the experimental drug is added to chemotherapy versus chemotherapy alone. After enrollment, participants are randomly assigned to one of the two groups, take the study medication daily in tablet form, and undergo regular clinic visits for treatment cycles and safety checks. The study continues until the disease progresses, the participant stops treatment, or the study ends, with follow‑up visits to monitor overall health and any side effects.

The purpose of the trial is to find out whether early use of adalimumab can lower the chance that the condition becomes severe disease compared with standard care. Participants who have non‑severe Hidradenitis suppurativa but are considered at high risk for worsening are randomly assigned to receive either the injection or the antibiotic. The study follows them for about two years, with regular clinic visits to check the skin and overall health. “Severe disease” is defined by either a classification called Hurley stage 3, which means many connected tunnels and lumps across the affected area, or an IHS4 score of 11 or higher, a simple tally of the number of nodules, abscesses and tunnels.

After an initial screening, participants start their assigned treatment and continue it for up to 104 weeks, returning to the clinic at set intervals for safety checks and to monitor any changes in their skin condition. The study does not involve any additional procedures beyond these routine visits.

The investigation tests a new oral medication called MK-7262 alone and in combination with a second oral agent, enlicitide decanoate. The goal is to see whether these medicines can lower the amount of the protein and the bad cholesterol more than a dummy pill (placebo).

Participants will take the assigned tablets once daily for several weeks, with regular check‑ins at the clinic to collect blood samples and report any side effects. The study lasts about two months, after which safety and how well the medicines worked are assessed.

The purpose of the study is to see whether a higher radiation dose improves overall survival. Participants will be randomly assigned to receive either the standard radiation dose or a higher dose, then all will continue with the same durvalumab treatment. The study follows patients for several months, checking how long they live, how the cancer responds, any side effects, and how they feel in daily life.

The purpose of the study is to determine how well this imaging test can identify the original location of the cancer and any spread, as well as to assess its ability to detect cancer that may return after treatment. Participants will receive an injection of the radioactive substance, wait a short period for it to circulate, and then undergo the scan. A follow‑up scan may be performed later to see any changes. “Staging” means finding the size and spread of cancer at diagnosis, while “restaging” refers to checking again after therapy. “Sensitivity” describes the test’s ability to correctly find cancer when it is present, “specificity” means correctly showing no cancer when it is absent, “predictive values” indicate how likely the results are to be correct, and “accuracy” reflects the overall correctness of the test.

The scan results will be compared with the tissue analysis that doctors perform after surgery to see if they match. The study will also look at whether the imaging changes the doctor’s view of the cancer stage, leads to different treatment choices, or reveals unexpected findings. Throughout the study, safety checks will be carried out to ensure that the injection and scanning procedure are well tolerated.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The purpose of the research is to compare how a protein called TSLP is produced in airway cells after they are exposed to a laboratory substance that mimics a virus, known as poly(I:C). Participants will have samples taken from their nose and lungs at the start of the study, receive the study medication, and then provide additional samples at later visits. The collected cells are placed in a lab where they are exposed to the viral mimic, and researchers measure changes in the amount of TSLP protein and its genetic instructions (mRNA). The study also looks at other cells involved in allergy and inflammation, such as eosinophils (a type of white blood cell) and mast cells (cells that release chemicals during allergic reactions), to see how they respond over time.